Neil Herring

Neil Herring

Auto-generated profile, based on publicly available information

Neil Herring

Burdon Sanderson Cardiac Science Centre, Department of Physiology, Anatomy and Genetics University of Oxford Oxford UK

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 June 2019 in Nature Reviews Cardiology
Verified
Journal Article
Closed access
PDF file
NHNeil Herring
Neil Herring
MKManish Kalla
Manish Kalla
DPDavid J. Paterson
David J. Paterson

19 September 2018 in Frontiers in Physiology
Verified
Journal Article
Open access
PDF file
Cheryl M. J. TanCheryl M. J. Tan
Cheryl M. J. Tan
PGPeregrine Green
Peregrine Green
NTNidi Tapoulal
Nidi Tapoulal
ALAdam Lewandowski
Adam Lewandowski
PLPaul Leeson
Paul Leeson
NHNeil Herring
Neil Herring
Neuropeptide Y (NPY) is an abundant sympathetic co-transmitter, widely found in the central and peripheral nervous systems and with diverse roles in multiple physiological processes. In the cardiovascular system it is found in neurons supplying the vasculature, cardiomyocytes and endocardium, and is involved in physiological processes including vasoconstriction, cardiac remodeling, and angiogenesis. It is increasingly also implicated in cardiovascular disease pathogenesis, including hypertension, atherosclerosis, ischemia/infarction, arrhythmia, and heart failure. This review will focus on the physiological and pathogenic role of NPY in the cardiovascular system. After summarizing the NPY receptors which predominantly mediate cardiovascular actions, along with their signaling pathways, individual disease processes will be considered. A thorough understanding of these roles may allow therapeutic targeting of NPY and its receptors.

17 June 2016 in The Journal of Physiology
Verified
Journal Article
Closed access
PDF file
JAJ. L. Ardell
J. L. Ardell
MAM. C. Andresen
M. C. Andresen
JAJ. A. Armour
J. A. Armour
GBG. E. Billman
G. E. Billman
PCP.‐S. Chen
P.‐S. Chen
IZI. H. Zucker
I. H. Zucker

27 February 2006 in QJM: An International Journal of Medicine
Verified
Journal Article
Closed access
PDF file
NHN. Herring
N. Herring
DPD.J. Paterson
D.J. Paterson
A century has passed since Einthoven published his description of the human electrocardiogram (ECG), recorded using a string galvanometer. The basic principles of this technique have remained unchanged, and it has revolutionized the diagnosis and management of cardiac pathology. At present, its sensitivity in diagnosing life-threatening myocardial infarction and ischaemia is inferior to that of biochemical markers. However, the ECG monitors cardiac function in real time, while biochemical assays can delay the diagnosis of acute myocardial infarction (AMI) and treatments that need to be delivered promptly. We review the historical development of the ECG and its limitations as a diagnostic tool for AMI, and highlight recent research into higher-resolution technologies for real-time cardiac monitoring, and how they may impact on chest pain management. Many distinguished scientists and clinicians have devoted their life's work to the use and understanding of the technique. This short review will merely highlight some of the more important contributions. The electrical activity of the heart was an incidental finding of Kolliker and Muller in 1856. 1 When a frog sciatic nerve/gastrocenemius preparation fell onto an isolated frog heart, both muscles contracted synchronously, suggesting that the heart generates electrical impulses. This activity was directly recorded and visualized using a Lippmann capillary electrometer by the British physiologist John Burdon Sanderson. 2 In 1887, Augustus Desire Waller used this technique to show that cardiac electrical potentials could be recorded via the limbs and directly from the chest of intact animals and humans. 3 The electrical activity preceded the heart's contraction, excluding an artefact caused by ‘a mechanical alteration of contact between the electrodes of the chest wall caused by the heart's impulse’. However, the clinical importance of his recordings was overlooked. Inspired by a demonstration by Waller, the Dutch physiologist Willem Einthoven began to develop capillary electrometer technology. This … Address correspondence to Dr N. Herring, Burdon Sanderson Cardiac Science Centre, Department of Physiology, Anatomy and Genetics, Sherrington Building, Parks Road, Oxford OX1 3PT. email: neilherring{at}doctors.org.uk

1 October 2015 in Heart Rhythm
Verified
Journal Article
Open access
RCRebecca A. Capel
Rebecca A. Capel
NHNeil Herring
Neil Herring
MKManish Kalla
Manish Kalla
AYArash Yavari
Arash Yavari
GMGary Richard Mirams
Gary Richard Mirams
RBRebecca-Ann B. Burton
Rebecca-Ann B. Burton
Bradycardic agents are of interest for the treatment of ischemic heart disease and heart failure, as heart rate is an important determinant of myocardial oxygen consumption. The purpose of this study was to investigate the propensity of hydroxychloroquine (HCQ) to cause bradycardia. We assessed the effects of HCQ on (1) cardiac beating rate in vitro (mice); (2) the "funny" current (If) in isolated guinea pig sinoatrial node (SAN) myocytes (1, 3, 10 µM); (3) heart rate and blood pressure in vivo by acute bolus injection (rat, dose range 1-30 mg/kg), (4) blood pressure and ventricular function during feeding (mouse, 100 mg/kg/d for 2 wk, tail cuff plethysmography, anesthetized echocardiography). In mouse atria, spontaneous beating rate was significantly (P < .05) reduced (by 9% ± 3% and 15% ± 2% at 3 and 10 µM HCQ, n = 7). In guinea pig isolated SAN cells, HCQ conferred a significant reduction in spontaneous action potential firing rate (17% ± 6%, 1 μM dose) and a dose-dependent reduction in If (13% ± 3% at 1 µM; 19% ± 2% at 3 µM). Effects were also observed on L-type calcium ion current (ICaL) (12% ± 4% reduction) and rapid delayed rectifier potassium current (IKr) (35% ± 4%) at 3 µM. Intravenous HCQ decreased heart rate in anesthetized rats (14.3% ± 1.1% at 15mg/kg; n = 6) without significantly reducing mean arterial blood pressure. In vivo feeding studies in mice showed no significant change in systolic blood pressure nor left ventricular function. We have shown that HCQ acts as a bradycardic agent in SAN cells, in atrial preparations, and in vivo. HCQ slows the rate of spontaneous action potential firing in the SAN through multichannel inhibition, including that of If.

11 July 2022 in Nature Cardiovascular Research
Verified
Journal Article
Open access
PDF file
JGJana Grune
Jana Grune
ALAndrew J. M. Lewis
Andrew J. M. Lewis
MYMasahiro Yamazoe
Masahiro Yamazoe
MHMaarten Hulsmans
Maarten Hulsmans
DRDavid Rohde
David Rohde
MNMatthias Nahrendorf
Matthias Nahrendorf
Sudden cardiac death, arising from abnormal electrical conduction, occurs frequently in patients with coronary heart disease. Myocardial ischemia simultaneously induces arrhythmia and massive myocardial leukocyte changes. In this study, we optimized a mouse model in which hypokalemia combined with myocardial infarction triggered spontaneous ventricular tachycardia in ambulatory mice, and we showed that major leukocyte subsets have opposing effects on cardiac conduction. Neutrophils increased ventricular tachycardia via lipocalin-2 in mice, whereas neutrophilia associated with ventricular tachycardia in patients. In contrast, macrophages protected against arrhythmia. Depleting recruited macrophages in Ccr2−/− mice or all macrophage subsets with Csf1 receptor inhibition increased both ventricular tachycardia and fibrillation. Higher arrhythmia burden and mortality in Cd36−/− and Mertk−/− mice, viewed together with reduced mitochondrial integrity and accelerated cardiomyocyte death in the absence of macrophages, indicated that receptor-mediated phagocytosis protects against lethal electrical storm. Thus, modulation of leukocyte function provides a potential therapeutic pathway for reducing the risk of sudden cardiac death.